Intermune CEO asks Supreme Court to review off-label marketing conviction

08/12/2013 | PharmaLive.com

Former Intermune CEO W. Scott Harkonen is asking the Supreme Court to review his conviction for wire fraud in a case involving off-label marketing of Actimmune. Harkonen issued a press release stating that a clinical trial confirmed Actimmune's efficacy against idiopathic pulmonary fibrosis, though the drug was not FDA-approved for that indication. Harkonen asserts that the conviction violates his right to free speech and that the statements he made were not false or misleading.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC